Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Lynn McCormick Matrisian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5631-2826; OpenAlex author ID A5080017108. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 5 papers · 2025: 4 papers · 2026: 2 papers

Papers 30

  1. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  2. Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer. Last author DOI 10.1093/jnci/djaf291↗
  3. Identifying signs and symptoms of pancreatic cancer: a population-based study using electronic health records and natural language processing. Co-author DOI 10.1016/j.pan.2025.05.005↗
  4. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  5. Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registry. Co-author DOI 10.1093/oncolo/oyaf406↗
  6. Understanding the Experiences of Patients With Pancreatic Cancer: Quantitative Analysis of the Pancreatic Cancer Action Network Patient Registry. Last author DOI 10.2196/65046↗
  7. Prediction of pancreatic cancer in patients with new onset hyperglycemia: A modified ENDPAC model. Co-author DOI 10.1016/j.pan.2024.09.015↗
  8. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  9. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  10. Keratin 17 modulates the immune topography of pancreatic cancer. Co-author DOI 10.1186/s12967-024-05252-1↗
  11. Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer. Co-author DOI 10.1200/cci.23.00119↗
  12. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Co-author DOI 10.1093/oncolo/oyad080↗
  13. Pre-Diagnosis Pain in Patients With Pancreatic Cancer Signals the Need for Aggressive Symptom Management. Last author DOI 10.1093/oncolo/oyad153↗
  14. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  15. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detectio… Co-author DOI 10.1016/j.cct.2021.106659↗
  16. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienc… Co-author DOI 10.1002/cam4.4257↗
  17. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  18. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. First author DOI 10.6004/jnccn.2020.7798↗
  19. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  20. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Co-author DOI 10.1097/mpa.0000000000001330↗
  21. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Co-author DOI 10.1200/po.19.00115↗
  22. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Co-author DOI 10.1080/15384047.2016.1210743↗
  23. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  24. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Development… Co-author DOI 10.3390/cancers10050142↗
  25. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Kno… Co-author DOI 10.18632/oncotarget.13225↗
  26. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. Co-author DOI 10.1001/jamaoncol.2016.0585↗
  27. The Past, Present, and Future of Pancreatic Cancer Clinical Trials. Co-author DOI 10.1200/edbk_159117↗
  28. Patient and caregiver awareness of pancreatic cancer treatments and clinical trials. First author DOI 10.3978/j.issn.2078-6891.2015.102↗
  29. Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. First author DOI 10.1016/j.pan.2015.05.471↗
  30. Pancreatic cancer clinical trials and accrual in the United States. Last author DOI 10.1200/jco.2013.49.4823↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bechien U. Wu · 5 shared papers, 2022–2026 · strength 1.17
  2. Suresh T. Chari · 6 shared papers, 2021–2026 · strength 1.08
  3. Anirban Maitra · 6 shared papers, 2021–2026 · strength 1.07
  4. Andrew Eugene Hendifar · 8 shared papers, 2017–2025 · strength 0.94
  5. Ziding Feng · 4 shared papers, 2021–2026 · strength 0.82
  6. Lola Rahib · 9 shared papers, 2013–2023 · strength 0.80
  7. Barbara J. Kenner · 4 shared papers, 2021–2026 · strength 0.75
  8. Sudheer Doss · 4 shared papers, 2021–2025 · strength 0.73
  9. Emanuel F. Petricoin · 6 shared papers, 2018–2024 · strength 0.72
  10. Michael Jon Pishvaian · 7 shared papers, 2017–2025 · strength 0.71
  11. Ying‐Qi Zhao · 3 shared papers, 2022–2026 · strength 0.66
  12. Jordan D. Berlin · 4 shared papers, 2016–2025 · strength 0.65
  13. Kawther Abdilleh · 3 shared papers, 2024–2025 · strength 0.61
  14. William E Fisher · 2 shared papers, 2026 · strength 0.52
  15. Fagen Xie · 2 shared papers, 2024–2025 · strength 0.51
  16. Wansu Chen · 2 shared papers, 2024–2025 · strength 0.51
  17. Tiffany Q. Luong · 2 shared papers, 2024–2025 · strength 0.51
  18. Vincent J. Picozzi · 4 shared papers, 2017–2024 · strength 0.47
  19. Allison Rosenzweig · 2 shared papers, 2023–2025 · strength 0.45
  20. Avinash R. Kambadakone · 2 shared papers, 2022–2026 · strength 0.44
  21. Wei Jiang · 3 shared papers, 2018–2024 · strength 0.39
  22. Jo Ann Rinaudo · 2 shared papers, 2022–2026 · strength 0.36
  23. Jonathan Robert Brody · 5 shared papers, 2017–2020 · strength 0.36
  24. Lucia Roa‐Peña · 2 shared papers, 2024 · strength 0.33
  25. Brent K. Larson · 2 shared papers, 2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.